HS
VRTX icon

HighVista Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

HighVista Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,752
Closed -$979K – 116
2022
Q1 		$979K Sell
3,752
-1,383
-27% -$328K 0.62% 35
2021
Q4 		$1.13M Buy
+5,135
New +$999K 0.9% 37

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

HighVista Strategies's VRTX Position: Q2 2022 in Review

HighVista Strategies sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 3,752 shares — an estimated $979K sold.

HighVista Strategies first reported a position in VRTX in Q4 2021 and held it in 2 quarters. The position peaked at $1.13M in Q4 2021. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • HighVista Strategies reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • HighVista Strategies sold 3,752 Vertex Pharmaceuticals shares in Q2 2022, an estimated $979K.
  • HighVista Strategies first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • HighVista Strategies's Vertex Pharmaceuticals position peaked at $1.13M in Q4 2021.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on HighVista Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.